US20120009290A1 - Compositions for skin diseases or disorders - Google Patents

Compositions for skin diseases or disorders Download PDF

Info

Publication number
US20120009290A1
US20120009290A1 US13/065,996 US201113065996A US2012009290A1 US 20120009290 A1 US20120009290 A1 US 20120009290A1 US 201113065996 A US201113065996 A US 201113065996A US 2012009290 A1 US2012009290 A1 US 2012009290A1
Authority
US
United States
Prior art keywords
tambourissa
extract
skin
composition
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/065,996
Other languages
English (en)
Inventor
Caroline Segond
Francoise Chanteloube
Alain Loiseau
Virginie Petit
Eric Theron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Consumer Care AG
Original Assignee
Bayer Consumer Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Consumer Care AG filed Critical Bayer Consumer Care AG
Assigned to BAYER CONSUMER CARE AG reassignment BAYER CONSUMER CARE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHANTELOUBE, FRANCOISE, LOISEAU, ALAIN, PETIT, VIRGINIE, SEGOND, CAROLINE, THERON, ERIC
Publication of US20120009290A1 publication Critical patent/US20120009290A1/en
Priority to US13/674,060 priority Critical patent/US9114115B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/002—Aftershave preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to medicaments and cosmetic compositions comprising Tambourissa plant extracts that in turn comprise polyphenols for the treatment or alleviation of skin or mucous membrane diseases or disorders related to an enhanced level of anti-microbial peptides or proteins.
  • This invention also relates to processes for preparing a Tambourissa plant extract, the extract itself, and uses of the extract.
  • the Tambourissa genus belongs to the Monimiaceae family and comprises about 43 species found throughout the western islands of the Indian Ocean, such as Madagascar, Comoros and the Mascarenes islands (Mauritius and Reunion).
  • the various Tambourissa species tend to show endemic specificity as most of them are localized in only one island and in only one habitat.
  • Tambourissa trichophylla (Baker) growths in Madagascar and Comoros. It is a tree of from about 5 meters to about 12 meters high. The leaves are opposite, oblong to lanceolate, from 8 to 20 cm long, dentate on the upper part. Male flowers are 5-6 mm in diameter, axillaris or terminal, from 1.5 to 3 cm long. Fruits are globes, about 4 cm in diameter, with coriaceus pericarp and numerous drupes. In Madagascar, this plant is called Amborahasa or Ambora and is traditionally used in health care, for instance for scar improvement and keloids (bark) or oral care (tea leaves as mouthwash).
  • Tambourissa species are also used in traditional treatments: crushed fresh leaves of Tambourissa microphylla are directly applied onto the skin for wound healing action, Tambourissa religiosa is used for tissue repair and Tambourissa capuronii (leaves crushed with liquid vegetal waxes) helps for dandruff treatment.
  • Tambourissa trichophylla is known to contain polyphenols and flavonoids, including epicatechin, nicotiflorin and rutin (Thesis of A. Lhuillier, L'Iinstitut National Polytechnique dedoch, 2007).
  • Polyphenols are a group of chemical substances found in plants, characterized by the presence of more than one phenol unit or building block per molecule. Polyphenols are generally classified as hydrolyzable tannins (gallic acid esters of glucose and other sugars) and phenylpropanoids, such as lignins, flavonoids, and condensed tannins. Polyphenols have been shown to have antioxidant characteristics with potential health benefits.
  • Flavonoids are widely distributed in plants and help plants carry out many functions including helping in the production of yellow or red/blue pigmentation in flowers and helping protect against attack by microbes and insects. Flavonoids have a widespread distribution in plants, come in a great variety and generally have low human toxicity. Flavonoids have been referred to as “nature's biological response modifiers” because of strong experimental evidence suggesting that flavonoids have an ability to modify the body's reaction to allergens, viruses, and carcinogens. Some flavenoids show anti-allergic, anti-inflammatory, anti-microbial and anti-cancer activity.
  • Rutin also called rutoside, is a citrus flavonoid glycoside having a structure similar to the flavonol quercetin and the disaccharide rutinose. It can be found in Ruta graveolens , buckwheat, the leaves and petioles of Rheum species, as well as other sources.
  • Rutin can combine with cations: in humans, it attaches to iron ions, Fe +2 , preventing iron from binding to hydrogen peroxide and from creating free-radical cellular damage. Rutin is also an antioxidant, and therefore can play a role in inhibiting some cancers. Rutin is also an anti-inflammatory agent. Rutin strengthens blood vessels, decreases the permeability of cell walls and acts as a vasodilatator. It can also act on edema in blood vessels and so decrease thrombosis risk. Rutin can help to decrease the cytoxicity of oxygenated DTL cholesterol, which may be one of the factors responsible for the development of atherosclerosis.
  • Epicatechin is also a flavonoid and is a major polyphenolic component of green tea ( Camellia sinensis ) and may also be found in other species. Epicatechin has been shown to be an anti-oxidant, to improve cardiovascular function, to increase blood flow in the brain and to be active against hepatotropic viruses.
  • Nicotiflorin is a flavonoid glycoside that can be found as such or as kaempferol-3-O-rutinoside glycosides in almonds ( Prunus dulcis ), green tea ( Camellia sinensis ), Carthamus tinctorius, Pogonatherum crinitum, Centaurea hierapolitana, Microcos paniculata, etc. Research on this compound has shown interesting properties with respect to its anti-oxidant potential, activity on blood circulation improvement. It is also a fibroblast growth promoter or can participate to anti-itching or to sunscreen activity.
  • a composition containing nicotiflorin is claimed for wrinkles prevention by inducing collagen synthesis and inhibiting collagenase.
  • Antimicrobial peptides or proteins are broad-spectrum antibiomicrobial compounds and correspond to one of the primary mechanisms used by the multiple epithelial surfaces (more specifically skin) in the early stages of immune defense.
  • AMPs include ⁇ - or ⁇ -defensin, RNase-7, S100-protein psoriasin or cathelicidin LL-37.
  • the antimicrobial activity deals with Gram positive and Gram negative bacteria but also with fungi and viruses.
  • the production of antimicrobial peptides or proteins by human skin occurs constitutively but seems also modulated after infection, inflammation or injury. Some skin diseases show altered expression of AMPs. For example their levels are increased in psoriatic lesions and decreased for atopic lesions (atopic dermatitis patients).
  • Cathelicidin is a cationic antimicrobial peptide expressed in most of the circulating immune cells (monocytes, leukocytes, neurophils etc) and also in epidermal keratinocytes. Cathelicidin is produced in various epithelia like skin or mucous membranes but also in sweat glands and sebocytes of the skin or scalp.
  • hCAP18 human Cathelicidin Anti-Microbial Peptide of 18 kDa—comprises a cathelin-like domain and a C-terminal peptide called LL-37 (a peptide beginning with 2 leucine residues that is 37 amino acids long).
  • cathelicidin is controlled by enzymatic processing of the proform (hCAP18) to a mature peptide (LL-37), which is induced by a proteolytic process involving kallikreins (such as Stratum corneum tryptic enzyme also called SCTE or kallikrein-5, S Stratum corneum chemotryptic enzyme also called SCCE or kallikrein-7).
  • kallikreins such as Stratum corneum tryptic enzyme also called SCTE or kallikrein-5, S Stratum corneum chemotryptic enzyme also called SCCE or kallikrein-7.
  • cathelicidin In healthy skin, epidermal keratinocytes express low amounts of cathelicidin. On infection or barrier disruption, cathelicidin is strongly induced and is either released by neutrophils or may be stored by keratinocytes in lamellar bodies. In case of wound healing, cathelicidin participates of course to microbial defense but also to the skin repair process as it activates pro-inflammatory cytokines synthesis, chemotaxis of immune cells, angiogenesis and proteoglycan expression. In rosacea, increased cathelicidin expression in the LL-37 peptide form has been observed—along with kallikreins activity activation. Abnormal AMP expression also exists in psoriasis as cathelicidin has been shown to be increased in psoriatic lesional skin.
  • U.S. Pat. No. 7,718,618 to Gallo et al. discloses the use of cathelicidin or related synthetic peptides for anti-microbial activity
  • U.S. Pat. No. 7,777,000 to Gallo et al. issued Aug. 17, 2010, describes anti-viral activity and such in dermatitis
  • PCT Patent Publication No. WO 2004/067025 also published as U.S. Pat. No. 7,452,864 to St ⁇ dot over (a) ⁇ le-Bumbledal, issued Nov. 18, 2008 discloses its use in wound healing by causing cell proliferation and regeneration.
  • European Patent Application No. 1,358,888 also published as U.S.
  • Rosacea is a chronic inflammatory disease, generally occurring on the face, which affects about 45 millions people worldwide. It corresponds to vascular disorder and is characterized by telangiectasia (visible hemorrhagic dilated blood capillaries near the skin surface), erythema, papules, and pustules primary in the central areas of the face combined with frequent burning and itching sensations. Rosacea affects mostly Caucasians of mainly northwestern European descent, and concerns both sexes, but is almost three times more common in women, and has a peak age of onset between 30 and 60.
  • the existing rosacea therapeutics which may be administered topically or administered systemically, include antibiotics, such as tetracycline, minocycline, erythromycin and doxycyline, azetromycin; anti-infectives, like azelaic acid, nadifloxacin, sodium sulfacetamide and metronidazole; anti-inflammatories with folic acids, nicotinamide and zinc oxide; Keratolysis activators, for example benzoyl peroxide, resorcinol and salicylic acid; and retinoids. These compounds and their formulations, however, are not always in rosacea and acne treatment.
  • antibiotics such as tetracycline, minocycline, erythromycin and doxycyline, azetromycin
  • anti-infectives like azelaic acid, nadifloxacin, sodium sulfacetamide and metronidazole
  • Topical applications of metronidazole cream or lotion with 0.75% to 1% active compound—are the most frequent treatment and have been shown to be effective when applied once or twice daily for 8-12 weeks. Some side effects related with use of metronidazole, including dry skin, skin redness or irritation, may occur.
  • Rosacea has multiple origins and may have causes like heredity, neurological disorders, gastric issues and other causes.
  • Main causes that can be alleviated by topical treatment include: (a) an over-expression of active forms of antimicrobial peptides (cathelicidins) and related enzymes, involved in the maintenance of an infectious status leading to skin chronic inflammation or being favorable to skin inflammation chronicity; (b) a vascular defect, which contributes to impaired capillary neoangiogenesis with frequent hemorrhagic characteristics, leading to the weakening of a skin that naturally tends to be thin and reactive; (c) inflammation, initially elusive but steadily increasing to become persistent with flush and blush phenomena; and (d) an inflammatory process depending to environmental conditions such as UVs or free radicals.
  • the principal object of the invention therefore is to provide an alternative new and possibly more advantageous compound or medicament for the treatment of skin or mucous membrane diseases related to an enhanced level of AMPs, to chronic or induced inflammation and to angiogenesis impairment.
  • Another object of the invention is to provide a cosmetic composition for the alleviation of skin or mucous membrane disorders related to an enhanced level of AMPs, to chronic or induced inflammation and to angiogenesis impairment.
  • a further objective of the present invention is to provide a method of treating diseases related to an enhanced level of AMPs with the medicament or cosmetic of the invention.
  • Another objective of the present invention is a method of treating diseases or disorders, especially skin or mucous membrane diseases or disorders, related to an enhanced level of AMPs with a Tambourissa plant extract, which may be a Tambourissa trichophylla plant extract, especially a leaf extract.
  • the invention provides a medicament, especially a topical medicament, for the treatment of skin diseases or mucous membrane diseases comprising a Tambourissa plant extract.
  • the present invention is further directed to a cosmetic composition
  • a cosmetic composition comprising a Tambourissa plant extract for the treatment of skin or mucous membrane disorders both related to an enhanced level of anti-microbial peptides or proteins, to chronic or induced inflammation and to angiogenesis impairment.
  • FIG. 1 shows modulation of expression in the Cathelicidin gene (CAMP) by the Tambourissa plant extracts of Example 4 and Table 3.
  • FIG. 2 show modulation of angiogenic factors by the Tambourissa trichophylla leaf extracts of Example 6 and Table 7. Induction is achieved by IL-17 only; the results of the Tambourissa plant extracts (Ambora) are displayed against a control.
  • FIG. 3 shows modulation of angiogenic factors by the Tambourissa trichophylla leaf extracts of Example 6 and Table 7. Induction is achieved by IL-17+ and Calictriol+LL37. The results of the Tambourissa plant extracts (Ambora) are displayed against a control.
  • the invention comprises a medicament or cosmetic agent comprising a Tambourissa plant extract for the treatment of skin diseases or mucous membrane diseases or a cosmetic composition comprising a Tambourissa plant extract for the treatment of skin or mucous membrane disorders both related to an enhanced level of anti-microbial peptides or proteins, to chronic or induced inflammation and to angiogenesis impairment.
  • Tambourissa extracts according to the invention are extracts of plants of the Tambourissa species, which include, but are not limited to, Tambourissa trichophylla, Tambourissa microphylla, Tambourissa religiosa and Tambourissa capuronii. Plant extracts of Tambourissa trichophylla are preferred.
  • the medicament or cosmetic composition of the invention can comprise an extract of all parts of the plant(s) and may also comprise mixtures of Tambourissa plant extracts.
  • the medicament or cosmetic composition may comprise an extract of the leaves of Tambourissa trichophylla.
  • the Tambourissa extract comprises polyphenols.
  • Preferred polyphenols of the invention are a group of chemical substances originally found in plants, characterized by the presence of more than one phenol unit or building block per molecule.
  • Polyphenols are generally grouped as hydrolysable tannins (gallic acid esters of glucose and other sugars) and phenylpropanoids, such as lignins, flavonoids, and condensed tannins.
  • Preferred polyphenols of the invention are flavonoids, and most preferred polyphenols are rutin, nicotiflorin, epicatechin and mixtures of these polyphenols.
  • the medicament or cosmetic composition of the invention comprises a Tambourissa plant extract, preferably a Tambourissa trichophylla extract, especially preferred a Tambourissa trichophylla leaf extract modulating, i.e. inhibiting and/or reducing, antimicrobial peptides or proteins (AMPs).
  • the medicament or cosmetic composition comprises Tambourissa extracts comprising polyphenols modulating, i.e. inhibiting and/or reducing, anti-microbial peptides or proteins (AMPs).
  • AMPs include ⁇ - or ⁇ -defensin, RNase-7, S100-protein psoriasin and the cathelicidin in pro- or active form (LL-37).
  • the inhibition and/or reduction of cathelicidin may be achieved in its pro or its activated form. Transformation of the pro-form may also be inhibited through inhibiting and/or reducing kallikrein synthesis.
  • the medicament or cosmetic composition it also modulates, i.e. reduces and/or inhibits, kallikrein synthesis.
  • the medicament of the invention may be used in the treatment of skin or mucous membrane diseases such as rosacea, acne, couperosis, erythrosis, telangiectasia, herpes, mouth infections, vaginal infections and/or sebaceous microbial infections, baby rash, dandruff, skin redness, skin blotchiness, atopic dermatitis, psoriasis, acanthosis, solar erythemas, after shave irritation, or itching.
  • skin or mucous membrane diseases such as rosacea, acne, couperosis, erythrosis, telangiectasia, herpes, mouth infections, vaginal infections and/or sebaceous microbial infections, baby rash, dandruff, skin redness, skin blotchiness, atopic dermatitis, psoriasis, acanthosis, solar erythemas, after shave irritation, or itching.
  • the cosmetic composition of the invention may be used for alleviating skin or mucous membrane disorders related to an enhanced level of anti-microbial peptides or proteins such as disorders associated with rosacea, acne, couperosis, erythrosis, telangiectasia, herpes, mouth infections, vaginal infections and/or sebaceous microbial infections, atopic dermatitis, psoriasis, acanthosis, or solar erythemas.
  • the medicament or cosmetic composition of the invention may be used to treat or alleviate baby rash, dandruff, skin redness and/or skin blotchiness, after shave irritation, or itching.
  • the invention may also be used in the regulation of microbial, fungal and viral diseases of the skin, scalp and mucous ecosystem (oral or vaginal mucosa, for example), especially maintenance or modulation following or associated with inflammatory responses.
  • Whether the dosage regimen of the invention depends on the severity of the symptoms and may be determined by a dermatologist or other medical personnel.
  • the medicament or cosmetic composition of the invention may also have anti-inflammatory activity, especially when it comprises the Tambourissa plant extract disclosed below.
  • the medicament or cosmetic composition of the invention can be destined to regulate epidermal, dermal, scalp or mucous membrane tissue homeostasis.
  • Homeostasis is defined in Roche Lexikon Medizin Edition 5.0 (2003 Elsevier, online version in German) as the self-regulation of a biological system (such as the scalp or mucous membrane tissue system) which is in a dynamic equilibrium, e.g., to ensure resistance against changing environmental conditions.
  • the invention may be used to restore and/or support the equilibrium of the skin against environmental and/or pathological conditions.
  • Inflammation is one of the first responses of the immune system to infection or irritation. Inflammation is stimulated by chemical factors released by injured cells and serves to establish a physical barrier against the spread of infection, and to promote healing of any damaged tissue following the clearance of pathogens. Chemical factors produced during inflammation (such as histamine, bradykinin, serotonin, leukotrienes, and prostaglandins) sensitize pain receptors, cause vasodilation of the blood vessels, and attract phagocytes, especially neutrophils. Neutrophils then trigger other parts of the immune system by releasing factors that will attract other leukocytes and lymphocytes. The inflammatory response may be characterized by redness, heat, swelling, pain and possible dysfunction of the organs or tissues affected by the inflammation.
  • Prolonged inflammation leads to a progressive shift in the type of cells that are present at the site of inflammation and is characterized by simultaneous destruction and healing of the tissue from the inflammatory process due to persistent acute inflammation due to non-degradable pathogens, persistent foreign bodies, or autoimmune reactions.
  • Autoimmune reactions can be linked to the involvement of lymphocytes and their specific differentiation towards different inducers into Th1, Th2 and/or Th17 leading to emphasizing some specific mediators, including Interleukine-1 (IL-1), IL-4 and IL-17.
  • IL-1 Interleukine-1
  • Psoriasis may be a mixed Th17/Th1 disease whereas atopic dermatitis may be a mixed Th17/Th2 disease.
  • the medicament or cosmetic composition of the invention is also active for inflammation modulation and the regulation of the inflammation drifts, for example in infections, chronic or induced inflammation, and aging.
  • the invention can reduce the synthesis of various pro-inflammatory agents in both inflammation pathways dealing with Cyclooxygenase (COX), Lipoxygenase (LOX) and with the subsequent formation of inflammatory messages (Prostaglandin-2, Leukotrienes, etc.).
  • COX Cyclooxygenase
  • LOX Lipoxygenase
  • the invention is also active in regulating interleukins, especially the impact of the interleukin-17 factor, nitric oxide and free radicals production.
  • the invention is also useful for treating sensitive skin and the disorders associated with acute inflammatory conditions or auto-immune diseases, such as, but not limited to, atopic dermatitis, psoriasis, acanthosis, baby rash, solar erythemas, after shave irritation, and itching.
  • acute inflammatory conditions or auto-immune diseases such as, but not limited to, atopic dermatitis, psoriasis, acanthosis, baby rash, solar erythemas, after shave irritation, and itching.
  • the medicament or cosmetic composition of the invention is active for angiogenesis regulation, more especially in downregulating the pro-angiogenic factors and upregulating the anti-angiogenic factors.
  • the medicament or cosmetic composition can thus be used for the treatment or alleviation of rosacea, couperosis, erythrosis, telangiectasia, skin redness and blotchiness.
  • a medicament is a pharmaceutical composition comprising at least one active compound or drug destined for diagnosis or therapy.
  • a medicament may influence the state or functioning of the body or affect the state or functioning of pathogens, parasites or xenobiotics with the aim of their removal.
  • a medicament may also aim at substituting body compounds or fluids.
  • the medicament (or cosmetic composition) of the invention can be administered in any form by any effective route, including, e.g., oral, parenteral, enteral, intravenous, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, via inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, and intrathecal, and any other useful and appropriate method of administration. Topical administration is preferred.
  • the invention can be administered alone, or in combination with any ingredient(s), active or inactive.
  • the medicament or cosmetic composition of the present invention can be formulated into known forms such as pharmaceutical or cosmetic compositions or compositions used as food supplements or as part of a medical device.
  • the formulations may be liquid or solid formulations such as, without limitation, normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, suppositories, syrups, solid and liquid aerosols, emulsions, pastes, creams, ointments, milks, gels, salves, serums, foams, shampoos, sticks or lotions.
  • a pharmaceutical or cosmetic composition in a form of topical pharmaceutical or cosmetic composition such as an aqueous solution, a white or colored cream, ointment, milk, gel, salve, serum, foam, shampoo, stick, cream, paste, or lotion.
  • topical pharmaceutical or cosmetic composition such as an aqueous solution, a white or colored cream, ointment, milk, gel, salve, serum, foam, shampoo, stick, cream, paste, or lotion.
  • the medicament or cosmetic composition of the present invention can be further combined with any other suitable additive or pharmaceutically or cosmetically acceptable carrier.
  • suitable additives include any of the substances already mentioned, as well as any of those used conventionally, such as those described in Remington: The Science and Practice of Pharmacy (Gennaro and Gennaro, eds, 20th edition, Lippincott Williams & Wilkins, 2000); Theory and Practice of Industrial Pharmacy (Lachman et al., eds., 3rd edition, Lippincott Williams & Wilkins, 1986); and Encyclopedia of Pharmaceutical Technology (Swarbrick and Boylan, eds., 2nd edition, Marcel Dekker, 2002). These materials are referred to herein as “pharmaceutically or cosmetically acceptable carriers” to indicate they are combined with the active drug or compound and can be administered safely to a subject for therapeutic or cosmetic purposes.
  • the dosage of the medicament or cosmetic composition of the invention can be selected with reference to the other and/or the type of disease or disorder and/or the disease or disorder status in order to provide the desired therapeutic or cosmetic activity.
  • These amounts can be determined routinely for a particular patient or person to be cosmetically treated, where various parameters are utilized to select the appropriate dosage (e.g., type of disease or disorder, age of patient, disease or disorder status, patient health, weight, etc.), or the amounts can be relatively standard and can be easily determined by a person skilled in the art.
  • the amount of the administered medicament or cosmetic composition can vary widely according to such considerations as the particular compound and dosage unit employed, the mode and time of administration, the period of treatment, the age, sex, and general condition of the patient or person to be treated, the nature and extent of the condition treated, the rate of drug or compound metabolism and excretion, the potential drug combinations and drug-drug interactions, and the like.
  • the medicament or cosmetic composition may comprise any amount of Tambourissa extract.
  • a medicament or cosmetic composition comprising the dried extract of Tambourissa trichophylla leaves as described below in an amount of from about 0.01% to about 5% by weight of the total composition is preferred.
  • the medicament or cosmetic composition according to the invention may be administered once or more, preferably up to three, and most preferably up to two times per day. Nevertheless, it may in some cases be advantageous to deviate from the amounts specified, depending on body weight, individual reactions to the active ingredient, type of pharmaceutical preparation and time or interval over which the administration is effected. For instance, less than the aforementioned minimum amounts may be sufficient in some cases, while the upper limit specified has to be exceeded in other cases. In the case of administration of relatively large amounts, it may be advisable to divide these into several individual doses over the day.
  • the medicament or cosmetic composition of the present invention can also be combined with at least one further active substance or plant extract e.g. substances or plant extracts usually employed for pharmaceutical, dermatological or cosmetic use.
  • Further active substances include, but are not limited to, desquamating and/or moisturizing agents, UV filtering or blocking agents, depigmenting or propigmenting agents, antiglycation agents, anti-inflammatory agents, anti-microbial agents, agents stimulating the synthesis of dermal, epidermal, hair or nail macromolecules and/or preventing the degradation thereof, agents stimulating the differentiation of keratinocytes, muscle relaxants, antipollution and/or anti-free radical agents, slimming agents, agents acting on the microcirculation, agents acting on the energy metabolism of the cells, tightening agents, agents preventing the loss or stimulating the growth of hair, agents preventing grey or white hair, or a mixture thereof.
  • the combination is contained in a topically dermatological composition.
  • the medicament or cosmetic composition may also contain at least one additional rosacea-effective agent, for example metronidazole, clindamycin, doxycycline, erythromycin, minocycline hydrochloride, tetracycline hydrochloride, azelaic acid, sodium sulfacetaminde, nicotinamide, benzyl peroxide, salicylic acid, adapalene, isotretinoid, tazarotene, or tretinoid.
  • additional rosacea-effective agent for example metronidazole, clindamycin, doxycycline, erythromycin, minocycline hydrochloride, tetracycline hydrochloride, azelaic acid, sodium sulfacetaminde, nicotinamide, benzyl peroxide, salicylic acid, adapalene, isotretinoid, tazarotene, or tretinoid.
  • the invention further comprises a process for preparing Tambourissa extracts.
  • these extracts are of plants of the Tambourissa species, which include, but are not limited to, Tambourissa trichophylla, Tambourissa microphylla, Tambourissa religiosa and Tambourissa capuronii. Tambourissa trichophylla is preferred.
  • the extraction can be performed on all parts of the plant(s), but the leaves of Tambourissa trichophylla are preferred.
  • the extraction can be done by standard extraction methods.
  • the extraction is carried out with a polar solvent applicable for extraction.
  • Leaves are first extracted with a polar solvent, e.g. mixtures of water and alcohol, optionally several times.
  • the obtained solution is then mixed, the alcohol is preferably removed and the precipitate is removed by filtration.
  • the whole polar solvent is removed and the residue is extracted with water.
  • the obtained polar phase is extracted with a non polar solvent e.g. ethyl acetate or heptane, to remove the waxes, essential oils, pigments and most of the non polar molecules.
  • the solvent of the remaining polar phase is removed in order to obtain a dry extract comprising polyphenols.
  • the extract may be dried by adding water followed by freeze-drying.
  • a process for preparing a Tambourissa trichophylla leaf extract may comprise the steps of: (a) extracting the leaves with a polar solvent mixture of water and alcohol; (b) removing the alcohol; (c) filtering the solution; and (d) extracting the obtained polar solution with a non-polar solvent to separate the extract.
  • the polar solvent used for extraction is preferably alcohol or a mixture of water and alcohol wherein the alcohol is preferably ethanol.
  • the ratio of the volume between water and alcohol can be from about 50:50 to about 90:10, preferably about 70:30.
  • the invention further comprises a Tambourissa trichophylla leaf extract.
  • the extract according to the invention can be prepared as described above or as disclosed in Example 1.
  • An extract according to the invention is normally a dry extract. Nevertheless the extract can also be used as solution, i.e. the final drying step of the extraction process may omitted, or the dry extract may be mixed with other liquid active compounds, or the dry extract may be incorporated in an optimized carrier to form a solution or other fluid state like an emulsion or dispersion.
  • the extract may also be encapsulated and the encapsulated extract may be dispersed in a fluid carrier.
  • Dry plant extracts that contain polyphenols in an amount of more than about 10% by weight with respect to the total plant extract are preferred, and extracts having more than about 15% by weight are more preferred. Extracts having from about 15% to about 45% by weight polyphenols are highly preferred, and extracts having from about 15% to about 35% by weight polyphenols are especially preferred.
  • Preferred polyphenols comprise flavonoids, and in a preferred embodiment of the invention the plant extract comprises from about 0.01% to about 20% by weight rutin, nicotiflorin and epicatechin.
  • rutin may be present in an amount of from about 0.01% to about 5% by weight
  • epicatechin may be present in an amount of about 0.01% to about 10% by weight
  • nicotiflorine may be present in an amount of from about 0.01% to about 5% by weight of the extract. While extracts comprising all three compounds are preferred, extracts containing one or two of these compounds may also be useful in the invention.
  • the invention further comprises the use of the Tambourissa extracts, preferably Tambourissa trichophylla extracts, and more preferably Tambourissa trichophylla leaf extracts, in the modulation of antimicrobial peptides or proteins, especially in the inhibition and/or reduction of cathelicidin and/or kallikrein synthesis.
  • the invention further comprises the use of the Tambourissa plant extracts for the treatment of skin diseases or disorders or mucous membrane diseases or disorders related to an enhanced level of anti-microbial peptides or proteins. It further comprises the use of the Tambourissa plant extracts as anti-inflammatory agents and as a regulator of angiogenesis.
  • Crushed dry leaves of Tambourissa trichophylla are extracted with a mixture of ethanol and water (in a volume ratio of 70:30).
  • the mixture is stirred and heated at a temperature below 60° C. for a period of about 30 minutes to about 1 hour to perform the extraction.
  • the solid plant material is removed, and ethanol is then removed leading to a precipitate, which is filtered out of the remaining aqueous solution.
  • the aqueous solution is then treated by liquid-liquid extraction with ethyl acetate. The acetate fraction is retained for acetate distillation and the consequent aqueous solution is freeze-dried.
  • the final extract is characterized by thin layer chromatography (TLC), using HPLC standard methods and spectrophotometry.
  • TLC thin layer chromatography
  • the final composition shows a content of 19% to 21% by weight of polyphenols and less than 2% by weight rutin and nicotiflorine.
  • the presence of epicatechin is also detected by TLC.
  • Emulsions containing various concentrations of Tambourissa trichophylla leaf extract were prepared in accordance with Example 1.
  • the emulsion concentrations are set forth in Table 1.
  • Phases A and B of the emulsions were weighed separately. The separate phases (A & B) were heated to 80° C. and mixed under high stirring A to B. The mixture was cooled down to 35° C. while stirring and component C was added. The compounds listed members of component D were mixed until a transparent solution was obtained and component D was then added to the formulation. The final formulation was cooled down to room temperature while stirring continued.
  • compositions were cosmetic oil in water emulsions: excipient (A) was white and formulations containing extract according to Example 1 (B & C) were beige to beige-orange.
  • HUVEC human umbilical vein endothelial cells
  • HUVEC human umbilical vein endothelial cells
  • HUVEC were incubated for 24 hours without (control) or with various concentrations of the extract from to example 1, and in presence of an inducer: VEGF (venous endothelial growth factor).
  • VEGF venous endothelial growth factor
  • PGE-2 levels were measured in the medium by the ELISA method. Significance was evaluated by the Student test.
  • the Tambourissa plant extract in the medicament or cosmetic composition of the invention can significantly modulate the cyclooxygenase pathway and therefore can have positive influence on inflammation state and thus be efficient in the treatment or alleviation of atopic dermatitis, psoriasis, acanthosis, baby rash, solar erythemas, after shave irritation, and itching.
  • CAMP Coronalcidin Anti-Microbial Peptide
  • the Culture medium was Keratinocyte-SFM (source: Invitrogen 17005075) supplemented with Epidermal Growth Factor (EGF) (0.25 ng/ml) (Invitrogen 10450-013), Pituitary extract (PE) (25 ⁇ g/ml) (Invitrogen 13028-014), and Gentamycin (25 ⁇ g/ml) (Sigma G1397).
  • EGF Epidermal Growth Factor
  • PE Pituitary extract
  • Gentamycin 25 ⁇ g/ml
  • the assay medium is Keratinocyte-SFM (Invitrogen 17005075) supplemented with Gentamycin (25 ⁇ g/ml) (Sigma G1397).
  • the extract obtained was solubilized in DMSO and tested at concentrations of 0.05, 0.5 and 5 ⁇ g/ml.
  • the keratinocytes were seeded in 24 well plates, in a culture medium. After 24 hours of pre-incubation, the culture medium was removed and replaced by assay medium containing or not containing (control) the test compound and the cells were incubated for 24 hours. After incubation the inducers were added and incubated for 48 hours. Tested inducers are calcitriol (Vitamin D3, (Sigma D-1530) at 10 ⁇ 7 M) or IL-17 ((R&D Systems 317-IL-050) at 10 ng/ml).
  • the PCR Polymerase Chain Reactions
  • ⁇ LightCycler®>> system Roche Molecular Systems Inc.
  • This system allows rapid and powerful PCR reactions, after determining the analysis conditions of the tested primers. It consists in two components: (a) a thermo-cycler: optimized for rapid PCR applications; allowing extremely rapid thermal transfers within the reaction mixture, and (b) a fluorimeter: allowing constant fluorescence measurement of the intercalating dye SYBR Green I; a dye that specifically binds to double-stranded DNA during the elongation cycle (detection wavelength: 521 nm).
  • the following primers couples were used to amplify the fragment corresponding to the selected marker.
  • Liver glyceraldehyde 3-phosphate dehydrogenase gene (G3PDH) was used as a reference marker.
  • the incorporation of fluorescence in amplified DNA was measured continuously during the PCR cycles.
  • Calcitriol or IL-17 and combination thereof highly stimulated the expression of the gene CAMP coding for hCAP-18/LL37.
  • the extract according to Example 1 Tambourissa trichophylla leaf extract or “Ambora”) dose-dependently reduces cathelicidin gene coding for LL37. This reduction can reach 40% (compared to control with induction) in case of IL-17 induction and 27% for calcitriol induction.
  • the Tambourissa plant extract in the medicament or cosmetic composition of the invention can therefore be active in cathelicidin-linked diseases or disorders and used for the treatment and alleviation of diseases or disorders such as rosacea, psoriasis or vaginal infections.
  • the objective of this study was to evaluate the efficacy of compositions containing different concentrations of the extract according to the invention.
  • the test was performed on two formulations containing 0.3% and 0.5% of the extract, respectively (formulations B and C from example 2).
  • the test was performed versus a placebo (formulation A of example 2).
  • the study was performed on 3 groups of 15 volunteers. Each group tested a different product. Evaluation was performed at the beginning of the study and after 28 and 56 days of twice-daily applications of the formulations A, B or C on the face.
  • the data showed a significantly higher activity on the microcirculation with 0.5% formulation product than with placebo at D28 and D56.
  • the data also show a significantly higher activity on the microcirculation with 0.5% formulation product than with 0.3% formulation at D56.
  • the decrease of skin redness and of the skin microcirculation makes formulations B and C, possible medicaments or cosmetic compositions comprising Tambourissa plant extract according to the invention, suitable for rosacea, erythrosis telangiectasis or skin redness/blotchiness treatment and/or alleviation.
  • the activity of the extract according to the invention was studied on pro-angiogenic factors expression by human keratinocytes.
  • the activity of Tambourissa extract ( 5 ⁇ g/ml) was tested by RT-q-PCR technology on RNA extracted from keratinocytes NHEK K(074) stimulated by the following inducers: LL-37 (20 ⁇ g/ml), IL-17 (10 ng/ml), vitamin D3 (10-6M), and combinations thereof.
  • the incorporation of fluorescence in amplified DNA was measured continuously during the PCR cycles. This resulted in a “fluorescence intensity” versus “PCR cycle” plot allowing the evaluation of a relative expression (RE) value for each marker.
  • the value selected for RE calculations is the “output point” (Ct) of the fluorescence curve. For a considered marker, the highest is the cycle number; the lowest is the mRNA quantity.
  • the culture medium was Keratinocyte-SFM supplemented with Epidermal Growth Factor (EGF) 0.25 ng/ml, Pituitary extract (PE) 25 ⁇ g/ml, and Gentamycin 25 ⁇ g/ml.
  • the assay medium was Keratinocyte-SFM supplemented with Gentamycin 25 ⁇ g/ml.
  • the effects (“treated” versus “control” condition) were measured by the scale set forth in Table 7.
  • the Tambourissa test plant extract is the tambourissa trichophylla leaf extract of Example 1. Under these experimental conditions, the Tambourissa plant extract of the invention partially reverse the effects of LL-37, IL-17 and vitamin D3, tested alone or in association, on the expression of angiogenic markers. In addition, the results also suggest that Tambourissa plant extract is an inhibitor of IL-17 (reduction of the impact of this pro-inflammatory agent).
  • the medicaments or cosmetic compositions comprising Tambourissa plant extract in accordance with the invention are thus understood to have a decreasing effect on pro-angiogenic gene expression rendering them suitable for rosacea, couperosis, erythrosis, telangiectasia, skin redness and blotchiness treatment and/or alleviation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
US13/065,996 2008-10-02 2011-04-04 Compositions for skin diseases or disorders Abandoned US20120009290A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/674,060 US9114115B2 (en) 2008-10-02 2012-11-11 Compositions for skin disease or disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP08290925 2008-10-02
EP08290925.0 2008-10-02
EP09290027 2009-01-13
EP09290027.3 2009-01-13
EP09290332.7 2009-05-07
EP09290332 2009-05-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/674,060 Continuation US9114115B2 (en) 2008-10-02 2012-11-11 Compositions for skin disease or disorders

Publications (1)

Publication Number Publication Date
US20120009290A1 true US20120009290A1 (en) 2012-01-12

Family

ID=41395939

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/065,996 Abandoned US20120009290A1 (en) 2008-10-02 2011-04-04 Compositions for skin diseases or disorders
US13/674,060 Expired - Fee Related US9114115B2 (en) 2008-10-02 2012-11-11 Compositions for skin disease or disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/674,060 Expired - Fee Related US9114115B2 (en) 2008-10-02 2012-11-11 Compositions for skin disease or disorders

Country Status (6)

Country Link
US (2) US20120009290A1 (ja)
EP (1) EP2331209A1 (ja)
JP (2) JP5714494B2 (ja)
KR (2) KR20170048606A (ja)
CA (1) CA2739001C (ja)
WO (1) WO2010037545A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
WO2023278812A1 (en) * 2021-07-02 2023-01-05 Winters Capital IP LLC A process for extracting bioactive compounds from plant materials

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013086518A1 (en) * 2011-12-09 2013-06-13 Mary Kay Inc. Skin care formulation
EP3287781B1 (en) * 2013-03-15 2024-04-17 The Procter & Gamble Company A noninvasive method for measuring antimicrobial peptides from skin as an objective measurement of natural protection from microbes
JP6393524B2 (ja) * 2014-06-05 2018-09-19 ロート製薬株式会社 保湿剤
FR3045385B1 (fr) * 2015-12-22 2019-12-20 Jean-Noel Thorel Composition cosmetique comprenant des inhibiteurs de l'expression du facteur de croissance nerveuse (nerve growth factor) pour le traitement du psoriasis, de la dermatite atopique et du prurit
KR20200002947A (ko) * 2017-04-28 2020-01-08 시므라이즈 아게 야로우 신선-식물 압착 주스 농축물, 생산, 및 용도
CN112370387B (zh) * 2020-11-03 2022-01-14 珀莱雅化妆品股份有限公司 一种具有头皮护理功效的植物双向发酵物的制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648496A1 (en) * 1993-10-15 1995-04-19 Bristol-Myers Squibb Company Therapeutic compositions for use in the treatment of skin lesions and method of making same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944313A (ja) * 1982-09-07 1984-03-12 Yakult Honsha Co Ltd 抗菌性組成物
JPS60208908A (ja) * 1984-03-31 1985-10-21 Kanebo Ltd 日焼け防止化粧料
US7314634B2 (en) * 2002-02-22 2008-01-01 Steven Hernandez Use of polyphenols to treat skin conditions
TW200533333A (en) * 2004-02-17 2005-10-16 Otsuka Pharma Co Ltd Human beta-defensin production accelerator
JP2007186457A (ja) * 2006-01-13 2007-07-26 Ichimaru Pharcos Co Ltd トリプターゼ活性阻害剤およびその利用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648496A1 (en) * 1993-10-15 1995-04-19 Bristol-Myers Squibb Company Therapeutic compositions for use in the treatment of skin lesions and method of making same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gallori et al, Identification of volatile constituents of Tambourissa leptophylla, Planta medica, (2001 Apr) Vol. 67, No. 3, pp. 290-2. *
Yoder et al, Tambouranolide, a new cytotoxic hydroxybutanolide from a Tambourissa sp. (Monimiaceae), Natural product research, (2007 Jan) Vol. 21, No. 1, pp. 37-4. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
WO2023278812A1 (en) * 2021-07-02 2023-01-05 Winters Capital IP LLC A process for extracting bioactive compounds from plant materials

Also Published As

Publication number Publication date
US9114115B2 (en) 2015-08-25
CA2739001A1 (en) 2010-04-08
WO2010037545A1 (en) 2010-04-08
JP2015078226A (ja) 2015-04-23
JP5714494B2 (ja) 2015-05-07
JP2012504564A (ja) 2012-02-23
CA2739001C (en) 2018-07-24
US20130071502A1 (en) 2013-03-21
EP2331209A1 (en) 2011-06-15
KR20110074857A (ko) 2011-07-04
KR20170048606A (ko) 2017-05-08

Similar Documents

Publication Publication Date Title
US9114115B2 (en) Compositions for skin disease or disorders
JP6215364B2 (ja) ＭＣ−１Ｒ、ＭＣ−２Ｒ、およびμオピオイド受容体調節
KR102257524B1 (ko) 피부 진정 및 재생효과를 지니는 병풀 유래 엑소좀 함유 피부 개선용 화장료 조성물
EP2677999B1 (en) Bioactive botanical cosmetic compositions and processes for their production
US20040091493A1 (en) Active ingredients stimulating type 2 and/or type 3 human beta-defensins and cosmetic or pharmaceutical compositions containing such active ingredients
KR100771397B1 (ko) 항산화 및 항염증 효과가 있는 민들레 추출물 또는이로부터 분리된 루테올린을 함유하는 화장료 조성물
US20090142285A1 (en) Cosmetic composition comprising ascorbic acid 2-glucoside and ergothioneine
JP5599730B2 (ja) 免疫細胞の活性化閾値を上昇させる物質
KR102171133B1 (ko) 병풀 추출물 및 개양귀비 추출물을 포함하는 피부 외용제 조성물
KR101225114B1 (ko) 봉독을 유효성분으로 함유하는 피부 미백 및 피부질환 예방 및 치료용 조성물
CN112386655A (zh) 大白蝴蝶兰萃取物用于制备抗醣化与改善皮肤外观的组合物的用途
CN111135124A (zh) 含有蔗糖、吲哚-3-乙酸以及玫瑰果提取物的混合物的皮肤外用剂组合物
KR102416652B1 (ko) 미세먼지로 인한 피부자극 완화 및 피부 개선용 화장료 조성물
EP3274347B1 (en) Compounds having antioxidant activity against free radicals and anti-inflammatory activity, and corresponding pharmaceutical compositions for skin care
KR102370802B1 (ko) 민들레 뿌리 추출물, 카페인 및 토코페롤의 혼합물을 포함하는 피부 외용제 조성물
KR101395004B1 (ko) 단마 추출물을 유효 성분으로 함유하는 피부 노화의 예방과 개선을 위한 조성물
BR112021003857A2 (pt) extrato botânico para cuidados com a pele
KR101604257B1 (ko) 람네틴을 유효성분으로 포함하는 자외선 자극에 의한 노화 및 염증에 대한 억제 활성을 동시에 가지는 조성물
KR102471051B1 (ko) 천연 소재를 이용한 홍조 및 아토피 예방 및 완화용 조성물 및 이를 포함하는 화장료
KR102098964B1 (ko) 신나무 추출물을 함유하는 탈모 질환의 예방, 치료 또는 개선용 조성물
KR102675988B1 (ko) 3,3',4-tri-O-methylellagic acid를 유효성분으로 포함하는 피부 개선용 조성물
KR101293066B1 (ko) 당귀 후박 양강 관계 추출물이 포함되고 약리활성이 있는 기능성 조성물 및 이를 포함하는 화장품 조성물, 구강청결용 조성물 그리고 모발제품 조성물
WO2024012787A1 (en) Composition comprising an extract of jasminum sambac and use thereof
KR20240028455A (ko) 솔라늄 리코퍼시쿰(Solanum lycopersicum) 열매(토마토) 껍질 추출물의 화장료 용도
KR20090113462A (ko) 피부 염증 예방 및 치료용 천연물 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAYER CONSUMER CARE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SEGOND, CAROLINE;CHANTELOUBE, FRANCOISE;LOISEAU, ALAIN;AND OTHERS;SIGNING DATES FROM 20110711 TO 20110901;REEL/FRAME:027063/0557

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION